Intellipharmaceutics International Inc
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, car… Read more
Intellipharmaceutics International Inc (IPCIF) - Net Assets
Latest net assets as of August 2023: $-12.88 Million USD
Based on the latest financial reports, Intellipharmaceutics International Inc (IPCIF) has net assets worth $-12.88 Million USD as of August 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.57 Million) and total liabilities ($14.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.88 Million |
| % of Total Assets | -822.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -357.82% |
| 10-Year Change | N/A |
| Growth Volatility | 516.07 |
Intellipharmaceutics International Inc - Net Assets Trend (2015–2022)
This chart illustrates how Intellipharmaceutics International Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intellipharmaceutics International Inc (2015–2022)
The table below shows the annual net assets of Intellipharmaceutics International Inc from 2015 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-11-30 | $-10.58 Million | -29.69% |
| 2021-11-30 | $-8.16 Million | -29.17% |
| 2020-11-30 | $-6.31 Million | -71.00% |
| 2019-11-30 | $-3.69 Million | -190.00% |
| 2018-11-30 | $4.10 Million | +961.72% |
| 2017-11-30 | $386.38K | -65.39% |
| 2016-11-30 | $1.12 Million | +910.73% |
| 2015-11-30 | $-137.69K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intellipharmaceutics International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5226165700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.18 Million | % |
| Other Components | $45.38 Million | % |
| Total Equity | $-10.58 Million | 100.00% |
Intellipharmaceutics International Inc Competitors by Market Cap
The table below lists competitors of Intellipharmaceutics International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thunderbird Resources Ltd
AU:THB
|
$4.88 Million |
|
Real Heart
ST:HEART
|
$4.88 Million |
|
BIO PLANET S.A. ZY 1
F:8WS
|
$4.88 Million |
|
Wahana Ottomitra Multiartha
JK:WOMF
|
$4.88 Million |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
$4.88 Million |
|
Plasson Indus
TA:PLSN
|
$4.87 Million |
|
Vertex Energy Inc
NASDAQ:VTNR
|
$4.87 Million |
|
Euromedis Groupe SA
PA:ALEMG
|
$4.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intellipharmaceutics International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -8,155,218 to -10,576,735, a change of -2,421,517.
- Net loss of 2,892,394 reduced equity.
- Other factors increased equity by 470,877.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.89 Million | -27.35% |
| Other Changes | $470.88K | +4.45% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Intellipharmaceutics International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-11-30 | $-0.07 | $0.15 | x |
| 2016-11-30 | $0.37 | $0.15 | x |
| 2017-11-30 | $0.11 | $0.15 | x |
| 2018-11-30 | $0.22 | $0.15 | x |
| 2019-11-30 | $-0.17 | $0.15 | x |
| 2020-11-30 | $-0.27 | $0.15 | x |
| 2021-11-30 | $-0.25 | $0.15 | x |
| 2022-11-30 | $-0.32 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intellipharmaceutics International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4400.55%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-442.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -181.65% | 0.78x | 0.00x | $-7.42 Million |
| 2016 | -908.71% | -451.43% | 0.28x | 7.14x | $-10.26 Million |
| 2017 | -2292.40% | -160.91% | 0.74x | 19.14x | $-8.90 Million |
| 2018 | -335.12% | -802.66% | 0.15x | 2.80x | $-14.16 Million |
| 2019 | 0.00% | -232.28% | 0.92x | 0.00x | $-7.72 Million |
| 2020 | 0.00% | -241.95% | 0.41x | 0.00x | $-2.76 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.33 Million |
| 2022 | 0.00% | -4400.55% | 0.05x | 0.00x | $-1.83 Million |
Industry Comparison
This section compares Intellipharmaceutics International Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intellipharmaceutics International Inc (IPCIF) | $-12.88 Million | 0.00% | N/A | $4.88 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |